Marker Therapeutics (NASDAQ:MRKR – Get Free Report) and Molecular Partners (NASDAQ:MOLN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Marker Therapeutics and Molecular Partners, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Marker Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Molecular Partners | 1 | 1 | 2 | 0 | 2.25 |
Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 952.63%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 110.27%. Given Marker Therapeutics’ higher probable upside, equities analysts clearly believe Marker Therapeutics is more favorable than Molecular Partners.
Institutional & Insider Ownership
Valuation and Earnings
This table compares Marker Therapeutics and Molecular Partners”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Marker Therapeutics | $3.55 million | 4.46 | -$12.16 million | ($0.41) | -2.32 |
| Molecular Partners | $5.65 million | 28.47 | -$74.41 million | ($1.71) | -2.33 |
Marker Therapeutics has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Marker Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Profitability
This table compares Marker Therapeutics and Molecular Partners’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
| Molecular Partners | N/A | -68.36% | -54.82% |
Summary
Marker Therapeutics beats Molecular Partners on 7 of the 11 factors compared between the two stocks.
About Marker Therapeutics
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
About Molecular Partners
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
